


EARLY TREATMENT PLAN FOR Active PREDOMINANTLY SYSTEMIC JIA and insufficient response to NSAIDs¹



JADAS= Juvenile Arthritis Disease Activity Scale. MD= Physicians global assessment of disease activity.

Footnote 1:

Anakinra 2-3mg/kg/day

Footnote 2: Ferritin>800, platelets < 150, ASAT >90, decrease in ESR, TG >

Footnote 3: Canakinumab, Tocilizumab

Footnote 4: Tocilizumab or TNF inhibitor

The treatment plan is based on the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Consensus treatment plans, expert reviews, the American College of Rheumatology (ACR) treatment plans.

References

1. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Nigrovic PA, Robinson AB, Vehe RK; American College of Rheumatology. *Arthritis Rheum*. 2013 Oct;65(10):2499-512.
2. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N. *Arthritis Care Res (Hoboken)*. 2011 Apr;63(4):465-82.
3. Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment. Calasan MB¹, Wulffraat NM. *Expert Rev Clin Immunol*. 2014 Jul;10(7):843-54.
4. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. *Arthritis Rheum* 2009 May 15;61(5):658-66.
5. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. [Horneff G](#) et al. *Arthritis Res Ther*. 2017 22;19(1):256.